Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | CA2 | P00918 | 6/20 | 0.47 |
| ▸ | CA4 | P22748 | 3/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 5/20 | 0.46 |
| ▸ | CA9 | Q16790 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31452114 | 1.00 | L3MBTL1 (0.53) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL636186 | 0.84 | L3MBTL1 (0.55) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL11318761 | 0.84 | CA1 (0.44) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL1406184 | 0.83 | L3MBTL1 (0.70) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL1807019 | 0.83 | L3MBTL1 (0.70) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL11327222 | 0.81 | CA12 (0.48) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL11334860 | 0.81 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL11327217 | 0.81 | ALDH1A1 (0.55) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL151537 | 0.81 | ALDH1A1 (0.54) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 | |
| SCHEMBL8493031 | 0.81 | L3MBTL1 (0.52) | L3MBTL1ALDH1A1KDM4ECYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954279-A | Composite flocculation settling agent and application thereof in treatment of heavy metal polluted water | 山东尚科环境工程有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-119194842-A | Method for preparing uniform and compact carbon coating on surface of carbon fiber | 山东理工大学 | 2024-12-27 | — | — | CN | claimed |
| CN-118315677-B | Wide-temperature-range electrolyte and preparation method and application thereof | 河北省科学院能源研究所 | 2024-10-01 | — | — | CN | claimed |
| CN-118315677-A | Wide-temperature-range electrolyte and preparation method and application thereof | 河北省科学院能源研究所 | 2024-07-09 | — | — | CN | claimed |
| CN-117187810-A | Microetching roughening solution for high-frequency high-speed circuit board and application thereof | 上海天承化学有限公司 | 2023-12-08 | — | — | CN | claimed |
| CN-114395129-A | Preparation method of polyether polyol with photodegradation characteristic | 山东一诺威新材料有限公司 | 2022-04-26 | — | — | CN | claimed |
| CN-107805212-B | Preparation method of 2-methyl-5-aminobenzenesulfonamide | 宿迁德威化工股份有限公司 | 2021-08-20 | — | — | CN | claimed |
| WO-2021162647-A1 | A NOVEL PROCESS FOR PREPARATION OF PAZOPANIB HYDROCHLORIDE | DEVA HOLDING (TR) | 2021-08-19 | — | — | WO | claimed |
| CN-109535044-B | Diazotization method of aromatic primary amine | 金华双宏化工有限公司 | 2021-06-15 | — | — | CN | claimed |
| CN-108963389-B | Gelable system for lithium-air battery and preparation method and application thereof | 北京师范大学 | 2020-11-13 | — | — | CN | claimed |
| CN-107058990-A | A kind of aqueous phase anti-rust cleaning agent | 广州天至环保科技有限公司 | 2017-08-18 | — | — | CN | claimed |
| EP-2646431-B1 | A PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2016-04-06 | — | — | EP | claimed |
| US-9150547-B2 | Process for the preparation of pazopanib using novel intermediate | HETERO RESEARCH FOUNDATION (IN) | 2015-10-06 | — | — | US | claimed |
| EP-2646431-A1 | A PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL INTERMEDIATE | Hetero Research Foundation (IN) | 2013-10-09 | — | — | EP | claimed |
| US-20130245262-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2013-09-19 | — | — | US | claimed |
| WO-2012073254-A1 | A PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL INTERMEDIATE | HETERO RESEARCH FOUNDATION (IN) | 2012-06-07 | — | — | WO | claimed |
| WO-2011069053-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIP HCL AND CRYSTALLINE FORMS OF PAZOPANIB HCL | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2011-06-09 | — | — | WO | claimed |
| EP-1761541-B1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | claimed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | claimed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245262-A1 | PROCESS FOR THE PREPARATION OF PAZOPANIB USING NOVEL INTERMEDIATE | PDGFRA, PDGFRB, FIP1L1 | L3MBTL1 4439/4885ALDH1A1 558/4885KDM4E 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.